Skip to content
Clinical Trials – home

Hospital Universitario De Jaen

Verified siteinfoFast reply

Spain Avenida Del Ejercito Espanol 10, 23007 Jaen, Spain

  • 50 trials recruiting
  • Non-small cell lung cancer · Breast cancer · Hormone receptor positive HER2 negative breast cancer
  • Adults and children

About Specializations

Hospital Universitario De Jaen in Jaen, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Hormone receptor positive HER2 negative breast cancer, Breast cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Breast Cancer Research

At Hospital Universitario De Jaen, a major share of the clinical trial portfolio focuses on neoplasms, especially breast cancer. Research includes early-stage, locally advanced, metastatic, and high-risk disease, with studies designed to improve treatment effectiveness, reduce recurrence, and refine care after surgery or neoadjuvant therapy.

  • Hormone receptor-positive and HER2-negative breast cancer
  • HER2-positive and triple-negative breast cancer
  • Metastatic and high-risk early breast cancer
  • Testing new combinations and supportive strategies to improve outcomes

This work reflects a strong focus on modern oncology care, with trials aimed at better disease control and more personalized treatment choices.

Lung Cancer and Thoracic Oncology

Another prominent area is respiratory tract disease research, particularly non-small cell lung cancer and small cell lung cancer. The trials explore treatment options for advanced, metastatic, and resectable disease, including studies that assess whether newer therapies can improve survival, delay progression, or support care after surgery.

  • Advanced and metastatic non-small cell lung cancer
  • Small cell lung cancer and limited-stage disease
  • EGFR-, RET-, KRAS-, and PD-L1-related lung cancer research
  • Evaluating new targeted and immunotherapy-based approaches

This area shows active investigation into more precise and effective treatment strategies for complex lung cancer cases.

Gynecologic, Hepatic, and Other Solid Tumors

The site also studies a broad range of other solid tumors, including ovarian cancer, endometrial cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and prostate cancer. These trials often aim to improve disease control in advanced or recurrent settings and to test whether new regimens can offer better outcomes for patients with limited options.

  • Ovarian, endometrial, and fallopian tube cancers
  • Head and neck cancer and hepatocellular carcinoma
  • Metastatic and unresectable solid tumors
  • Assessing new therapies for harder-to-treat cancers

The research portfolio highlights a broad oncology focus beyond breast and lung cancer, with attention to both tumor control and long-term benefit.

Cardiovascular and Metabolic Disease Studies

Clinical trials at the site also address cardiovascular diseases and nutritional and metabolic diseases. Research includes conditions such as atherosclerotic cardiovascular disease, hypertension, spontaneous coronary artery dissection, transthyretin amyloid cardiomyopathy, and type 2 diabetes, with studies focused on improving prevention and treatment.

  • Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
  • Hypertension, heart failure, and coronary disorders
  • Type 2 diabetes and severe hypertriglyceridemia
  • Testing therapies that may reduce events and improve long-term health

This research supports better management of chronic cardiometabolic conditions that affect many adults.

Infections, Immune, and Skin-Related Conditions

The trial landscape at Hospital Universitario De Jaen includes studies in bacterial infections and mycoses, immune system diseases, and skin and connective tissue diseases. Examples include bacteremia, septic shock, allergic rhinitis with asthma, and atopic dermatitis, with research aimed at improving treatment effectiveness, safety, and symptom control.

  • Bloodstream infections and septic shock
  • Allergic and immune-mediated conditions
  • Atopic dermatitis and related skin disease
  • Comparing treatments to improve outcomes and reduce side effects

These studies show a balanced interest in both acute infectious disease care and longer-term immune-mediated conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Del Ejercito Espanol 1023007 JaenSpain
Recruiting now
50 trials
Conditions studied
83
Partner status
Verified site

More sites in JaenSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

130 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Ticagrelor, Acetylsalicylic Acid and Prasugrel in Patients with Acute Coronary Syndrome: A Study of Antiplatelet Management

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.